3 Breast Cancer Drugs With Big Potential
In 2010, $16.5 billion was spent on breast cancer treatment in the U.S. and as much as $25 billion could be spent treating the disease by 2010, according to the National Cancer Institute. Additionally, the World Health Organization reports that 1.4 million new cases are diagnosed each year and that more than 450,000 die annually from the cancer.
That means there's a significant and growing need for new and better treatments for this significant and important disease. Fortunately, three companies are working on intriguing new compounds that may offer new hope for patients.
Pfizer , Novartis , and Eli Lilly are developing new drugs that target a specific enzyme known as CDK 4/6. So far, Pfizer's palbociclib is the closest to reaching the market, but Novartis and Lilly aren't far behind it.
In the following slideshow, you'll learn more about Pfizer, Novartis, and Lilly's drugs and how they may help breast cancer patients in the future.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
The article 3 Breast Cancer Drugs With Big Potential originally appeared on Fool.com.Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.